(S (NP (DT An) (JJ innovative) (NN approach) (S (VP (TO to) (VP (VB analyze) (NP (NP (DT the) (NN complexity)) (PP (IN of) (S (VP (VBG translating) (NP (JJ novel) (JJ molecular) (NNS entities) (CC and) (NNS nanomaterials)) (PP (IN into) (NP (JJ pharmaceutical) (NNS alternatives))))))) (PRN (-LRB- -LRB-) (NP (ADVP (FW i.e.)) (, ,) (NN knowledge) (NN translation)) (, ,) (NP (NNP KT)) (-RRB- -RRB-)))))) (VP (VBZ is) (VP (VBN discussed))) (. .))
(S (ADVP (RB First)) (, ,) (NP (NP (DT some) (JJ key) (NNS concepts)) (PP (IN on) (NP (NP (DT the) (NN organization) (CC and) (NN translation)) (PP (IN of) (NP (DT the) (JJ biomedical) (NN knowledge) (PRN (-LRB- -LRB-) (NP (NNS paradigms)) (, ,) (NP (ADVP (RB homophily)) (, ,) (NP (NN power) (NN law) (NNS distributions)) (, ,) (NP (NN hierarchy) (, ,) (NN modularity) (, ,) (CC and) (NN research)) (NP (NNS fronts))) (-RRB- -RRB-))))))) (VP (VBP are) (VP (VBN reviewed))) (. .))
(S (ADVP (RB Then)) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (NN model)) (PP (IN for) (NP (DT the) (NN knowledge) (NN translation) (PRN (-LRB- -LRB-) (NP (NNP KT)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NNP Drug) (NNP Discovery)) (SBAR (WHNP (WDT that)) (S (VP (VBZ considers) (NP (NP (DT the) (NN complexity)) (PP (IN of) (NP (JJ interdisciplinary) (NN communication)))))))))) (. .))
(S (S (ADVP (RB Specifically)) (, ,) (NP (PRP we)) (VP (VBP address) (NP (CD two) (ADJP (RB highly) (JJ relevant)) (NNS aspects)))) (: :) (S (LST (LS 1) (-RRB- -RRB-)) (NP (DT A) (JJ successful) (NNP KT)) (VP (VBZ requires) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (NP (NP (VBN organized) (NNS bodies)) (PP (IN of) (NP (NN inter-and) (JJ transdisciplinary) (NN research)))) (, ,) (CC and) (NP (LST (LS 2) (-RRB- -RRB-)) (NP (DT The) (ADJP (JJ hierarchical) (CC and) (JJ modular)) (JJ topological) (NN organization)) (PP (IN of) (NP (DT these) (NNS bodies))) (PP (IN of) (NP (NN knowledge))))))))) (. .))
(S (NP (PRP We)) (VP (VBD focused) (PP (IN on) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (ADJP (RB previously) (HYPH -) (VBN published)) (NNS studies))))) (PP (IN on) (NP (NP (NNP KT)) (SBAR (WHNP (WDT which)) (S (VP (VBP rely) (PP (IN on) (NP (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NN network) (NN analysis)))) (CC and) (NP (NP (ADJP (NN computer) (HYPH -) (VBN assisted)) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NNS contents)) (PP (IN of) (NP (JJ scientific) (NN literature) (CC and) (NNS patents)))))))))))))) (. .))
(S (NP (DT The) (VBN selected) (NNS studies)) (VP (VBP provide) (NP (NP (NP (DT a) (NN duo)) (PP (IN of) (NP (JJ complementary) (NNS perspectives)))) (: :) (NP (NP (DT the) (NN demand)) (PP (IN of) (NP (NP (NP (NP (NN knowledge)) (-LRB- -LRB-) (NP (NML (NML (JJ cervical) (NN cancer)) (CC and) (NML (NNP Ebola))) (JJ hemorrhagic) (NN fever)) (-RRB- -RRB-)) (CC and) (NP (NP (DT the) (NN supply)) (PP (IN of) (NP (NN knowledge))))) (-LRB- -LRB-) (NP (NP (NNS liposomes) (CC and) (NNS nanoparticles)) (SBAR (S (VP (TO to) (VP (VB treat) (NP (NP (NN cancer)) (CC and) (NP (DT the) (JJ paradigmatic) (NNP Doxil)))))))) (, ,) (NP (DT the) (JJ first) (NN nanodrug) (S (VP (TO to) (VP (VB be) (VP (VBN approved)))))) (-RRB- -RRB-)))))) (. .))
